HOME >> BIOLOGY >> NEWS
Gene therapy holds promise for treating inherited Lou Gehrig's Disease

CHICAGO --- Using gene therapy in laboratory mice, researchers have halted motor neuron destruction and slowed progression of inherited amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, a lethal, progressive neurological disorder that renders the muscles of the body useless while leaving the mind unaffected.

This finding suggests that a similar gene therapy approach might someday prove effective in treating humans with ALS, according to Northwestern University developmental neurobiologist Martha C. Bohn and colleagues in an article in the July 15 issue of Human Gene Therapy.

Bohn is a professor of pediatrics at Northwestern University Medical School and director of the neurobiology program at Children's Memorial Institute for Education and Research.

Into the hindlimbs of an ALS mouse model, Bohn and co-researchers injected young skeletal muscle cells (myoblasts) infected with a virus that had been made harmless and also engineered to carry the gene for glial cell-derived neurotrophic factor (GDNF). GDNF is a protein that has been found to block nerve cell degeneration in animal models of Parkinson's disease.

The GDNF gene therapy enhanced survival of motor neurons in the laboratory model of inherited ALS and increased the number of motor neurons that maintained 'communication' with cells in treated leg muscles. Additionally, GDNF gene therapy slowed shrinkage of motor neurons and muscle atrophy, improved motor function in affected mice and delayed onset of ALS disease symptoms.

"The most critical issues in designing a gene therapy approach for any human disease are to have a good animal model of the disease and to choose the appropriate target tissue and mode of gene delivery," Bohn said.

The mice used in this study express a mutant gene that is carried by humans with a hereditary form of ALS. These mice were developed by Mark Gurney and Teepu Siddique, professor of neuro
'"/>

Contact: Elizabeth Crown
e-crown@nwu.edu
312-503-8928
Northwestern University
19-Jul-1999


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... SOMERSET, N.J. (PRWEB) , ... August 25, 2020 ... ... technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and ... the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA ... , a Clinical Operations executive with expertise in clinical trial planning and feasibility, ... as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... validation engineering firm, is making available for free its new white paper ... concurrent transport simulation testing into today’s biologics licensing application (BLA). In response, ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International ... only $3950. With 50 million stem cells total, patients may choose which extremities they ... works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the solution ... history of eSource, the reasons it did not take off as quickly as people ... the industry is moving towards capturing data electronically for clinical trials and then repurposing ...
(Date:7/18/2020)... , ... July 16, 2020 , ... “We are thrilled ... Wave Bioactives. “It’s the only technology of its kind on the market and we ... onions with the protective capacity of traditional cultured ingredients, creating a natural way to ...
Breaking Biology Technology:
Cached News: